Determining potential immunomodulatory drug efficacy in sepsis using ELISpot
Andrew H. Walton(Washington University in St. Louis), Richard S. Hotchkiss(Washington University in St. Louis), Charles C. Caldwell(University of Cincinnati Medical Center), Anne M. Drewry(Washington University in St. Louis), Ethan Davitt(Washington University in St. Louis), Tyler J. Loftus(University of Florida), R. W. Gould(University of Minnesota Medical Center), Thomas S. Griffith(University of Minnesota), Lyle L. Moldawer(University of Florida), Kenneth E. Remy(Washington University in St. Louis), Ricardo Ungaro(University of Florida), Monty B. Mazer(Rainbow Babies & Children's Hospital), Scott C. Brakenridge(University of Florida), Vladimir P. Badovinac(Carver Bible College), Ivanna Rocha(University of Florida), Dale F. Osborne(Washington University in St. Louis), Philip A. Efron(University of Florida)
Cited by 7
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
Genomic responses in mouse models poorly mimic human inflammatory diseases
|Proceedings of the National Academy of Sciences|2013|3k
Sepsis and septic shock
|Nature Reviews Disease Primers|2016|1.6k
MyD88-dependent expansion of an immature GR-1+CD11b+ population induces T cell suppression and Th2 polarization in sepsis
|The Journal of Experimental Medicine|2007|647